GLI1 and skin basal cell carcinoma: Results from this secondary analysis suggest that sonidegib treatment led to substantial reductions in GLI1 levels from baseline across doses, BCC subtypes, examined time points, and demographic and baseline disease characteristics in patients with advanced BCC.